Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01667679 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura
A Phase 3 study, sponsored by Avanir Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 275
- Enrollment target
NCT01667679 is a Phase 3 study that has completed, run by Avanir Pharmaceuticals. The registered enrollment target is 275 participants.
The verdict
NCT01667679, a Phase 3 study, has completed, sponsored by Avanir Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 275 participants
- Enrollment target
Study Summary
This study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN DEVICE can reduce the pain associated with migraine headaches in 30 minutes after use.
Interventions
- DRUG 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally
- DRUG OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01667679
The ClinicalTrials.gov registry entry for NCT01667679 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avanir Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally is the first listed.
NCT01667679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01667679 about?
NCT01667679 is a clinical study titled "Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura". This study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN DEVICE can reduce the pain associated with migraine headaches in 30 minutes after use.
What is the current status of trial NCT01667679?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 275 participants. The study started on 2012-08. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01667679?
The interventions under investigation include: 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally (DRUG), OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet (DRUG).
Who is sponsoring clinical trial NCT01667679?
This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.